SFC CE: BTE209

徽信: zhuangcharles; 电话: (852) 9748 7114;

2 Sep 2025



阜丰集团 Fufeng Group Limited (0546.HK)

25H1 归母净利润同比增长 72.1%, 受益于新增产能释放 25H1 Profit +72.1% YoY & Release of new production capacity

最新动态

- 2025H1 归母净利润同比增长 72.1%。25H1,公司取得收入 139.60 亿元,同比增加 4.4%;归母净利润 17.92 亿元,同比增加 72.1%。25H1,公司收入增加主要由于动物营养分部收入增长所致。公司归母净利润增加主要由于:(1)产品(包括味精、苏氨酸及赖氨酸)销量增加及主要原材料(包括玉米及煤)成本下降导致毛利增加,从而增加股东应占溢利;及(2)收到新疆梅花及梅花生物赔偿人民币 2.33 亿元。
- ▶ 新增产能释放。25H1, 1) 40 万吨的味精新增产能已在 25H1 全面投产。2) 苏氨酸销量增加反映市场已消化公司于 2024 年投产的 2 万吨苏氨酸新增产能。3) 赖氨酸销量增加反映市场已消化公司于 2024 年投产的 10 万吨苏氨酸新增产能。
- **国际化进程取得突破。**公司位于哈萨克斯坦的首个海外生产基地已于25H1动工。公司在哈萨克斯坦斯坦发展的第一阶段投资目标约为3.50亿美元。公司计划于发展的第一阶段制造及销售动物营养及高档氨基酸产品。

动向解读

- ▶ 产品价格承压。1) 25H1,食品和饮料市场对味精的需求持续低迷,且下游客户需求仍然疲弱,导致味精价格在低水平徘徊。根据卓创信息的数据,25H1味精的平均价格为每吨约人民币7180元,同比减少9.1%。2)黄原胶的价格自2024年起逐渐回落至相对合理水平,且25H1市场上出现新产量亦进一步对黄原胶的价格造成压力。根据卓创信息的数据,25H1的黄原胶的平均价格同比下跌13.7%至每吨约人民币21990元。3)受惠于海外需求增加,使苏氨酸和98%赖氨酸的价格自2024H2逐渐上升。然而,由于苏氨酸及98%赖氨酸的分部尚未整合,市场上不断出现新产能,对价格造成压力。苏氨酸及98%赖氨酸于25H1的价格未能延续上升趋势,并回落至2024H1的水平。
- ▶ 原材料及能源成本有所下降。25H1, 玉米颗粒占总生产成本约54.9%(24H1:58.2%)。25H1 玉米颗粒平均价格(主要原材料成本)为每吨约人民币1780元,同比减少14.3%。25H1, 玉米颗粒的总成本下降1.7%,乃由于玉米平均价格同比有所下跌。煤炭成本为主要的能源成本。25H1,煤炭占总生产成本约16.0%(24H1:16.6%)。25H1,煤炭平均单位成本为每吨约人民币349元,同比下跌10.3%。集团的主要生产基地有其自身的发电厂,通过直接自签订长期合约的当地煤矿中采购煤炭,尽享该等地区低成本煤炭之利,以保证公司的煤炭供应量。

策略建议

▶ **盈利预测。**我们预计公司 2025-2027 年归母净利润分别为 30.39 亿元、33.50 亿元和 36.47 亿元。考虑到同行业可比公司估值,我们给予公司 2025 年 8.5 倍 PE,对应目标价为 10.29 元,按港币兑人民币汇率为 0.91 计算,对应目标价为 11.30 港元,给予为"买入"评级。



主要财务数据及预测

	2024	2025E	2026E	2027E
营业收入	27757	28471	29774	31265
(+/-) (%)	-1%	3%	5%	5%
归母净利润	2312	3039	3350	3647
(+/-) (%)	-26%	31%	10%	9%
EPS	0.92	1.21	1.34	1.45
P/E	5.49	7.04	6.39	5.87

资料来源:公司年报(2024),环球富盛;备注:净利润为归属母公司所有者的净利润

可比上市公司估值比较								
八二万仏 明而此初	股价		EPS(元/股)		PE (倍)			
公司名称	股票代码	(元)	2024	2025E	2026E	2024	2025E	2026E
600873.SH	梅花生物	10.98	0.96	1.12	1.23	9	10	9
600866.SH	星湖科技	7.91	0.57	0.85	0.90	16	9	9
平均						13	10	9

资料来源: Wind, 环球富盛, 股价为 2025 年 9 月 1 日收盘价, 每股收益均为 Wind 一致预期

风险提示

产品价格波动的风险、原材料价格波动的风险。



财务报表分析和预测

资产负债表	2024	2025E	2026E	2027E	利润表	2024	2025E	2026E	2027E
流动资产	22,532	24,362	26,108	27,897	营业收入	27,757	28,471	29,774	31,265
现金	9,902	11,691	12,882	14,034	其他收入	0	0	0	0
应收账款及票据	2,003	2,056	2,150	2,258	营业成本	22,700	22,022	23,074	24,284
存货	6,135	5,995	6,281	6,611	销售费用	1,964	2,278	2,233	2,189
其他	4,493	4,620	4,795	4,994	管理费用	1,091	1,224	1,072	1,094
非流动资产	13,558	13,828	14,040	14,239	研发费用	0	0	0	0
固定资产	12,409	12,634	12,846	13,045	财务费用	-295	-126	-179	-214
无形资产	74	74	74	74	除税前溢利	2,837	3,729	4,111	4,475
其他	1,075	1,119	1,119	1,119	所得税	525	690	760	828
资产总计	36,090	38,190	40,148	42,136	净利润	2,312	3,039	3,350	3,647
流动负债	16,240	16,382	16,678	17,012	少数股东损益	0	0	0	0
短期借款	11,016	11,066	11,116	11,166	归属母公司净利润	2,312	3,039	3,350	3,647
应付账款及票据	1,973	1,896	1,987	2,091					
其他	3,251	3,419	3,575	3,754	EBIT	2,542	3,602	3,931	4,261
非流动负债	1,506	1,552	1,552	1,552	EBITDA	3,674	4,377	4,720	5,062
长期债务	348	348	348	348	EPS (元)	0.92	1.21	1.34	1.45
其他	1,158	1,204	1,204	1,204					
负债合计	17,747	17,934	18,230	18,564					
普通股股本	241	241	241	241					
储备	18,110	20,023	21,685	23,340					
归属母公司股东权益	18,343	20,256	21,918	23,573					
少数股东权益	0	0	0	0					
股东权益合计	18,343	20,256	21,918	23,573	主要财务比率	2024A	2025E	2026E	2027E
负债和股东权益	36,090	38,190	40,148	42,136	成长能力				
					营业收入	-0.89%	2.57%	4.58%	5.01%
					归属母公司净利润	-26.45%	31.42%	10.24%	8.87%
					获利能力				
					毛利率	18.22%	22.65%	22.50%	22.33%
					销售净利率	8.33%	10.67%	11.25%	11.67%
					ROE	12.61%	15.00%	15.28%	15.47%
					ROIC	6.97%	9.27%	9.60%	9.90%
					偿债能力				
					资产负债率	49.17%	46.96%	45.41%	44.06%
					净负债比率	7.97%	-1.36%	-6.47%	-10.69%
					流动比率	1.39	1.49	1.57	1.64
					速动比率	0.82	0.93	0.99	1.05
现金流量表	2024	2025E	2026E	2027E	营运能力				
经营活动现金流	2,955	3,322	3,406	3,641	总资产周转率	0.81	0.77	0.76	0.76
净利润	2,312	3,039	3,350	3,647	应收账款周转率	13.44	14.03	14.16	14.18
少数股东权益	0	0	0	0	应付账款周转率	13.41	11.38	11.88	11.91
折旧摊销	1,131	775	788	801	毎股指标(元)				
营运资金变动及其他	-488	-492	-733	-807	每股收益	0.92	1.21	1.34	1.45
加水火山州人中					每股经营现金流 5 m 4 2 2 3	1.18	1.32	1.36	1.45
投资活动现金流	-1,100	-287	-404	-374	每股净资产	7.32	8.08	8.74	9.40
资本支出	-1,221	-1,000	-1,000	-1,000	估值比率 D/D	5.40	7.04	0.00	5.07
其他投资	121	713	596	626	P/E	5.49	7.04	6.39	5.87
笙次江山坝人坛	4 007	4 0 4 0	4.040	0.445	P/B	0.69	1.06	0.98	0.91
筹资活动现金流 借款增加	1,097	-1,246	-1,810 50	-2,115 50	EV/EBITDA	3.84	4.83	4.24	3.73
信款增加 普通股增加	1,599	50	50	50					
音通版增加 已付股利	-73 1 210	1 126	1 600	1 003					
	-1,219 -701	-1,126	-1,688 470	-1,992					
其他 现金净增加额	791	-171	-172	-172					
加速守有が映	3,046	1,788	1,192	1,152					

备注: (1) 表中计算估值指标的收盘价日期为 2025年 9月 1日; (2) 以上各表均为简表

资料来源: Wind, 环球富盛



What's New

- The net profit increased by 72.1% YoY in 2025H1. In 25H1, the company achieved a revenue of 13.96 billion yuan (+4.4% YoY); The net profit was 1.792 billion yuan (+72.1% YoY). In 25H1, the increase in company revenue is mainly due to the growth in revenue of the animal nutrition division. The increase in net profit attributable to the parent company is mainly due to: (1) an increase in sales of products (including monosodium glutamate, threonine, and lysine) and a decrease in the cost of major raw materials (including corn and coal), resulting in an increase in gross profit, thereby increasing the profit attributable to shareholders; And (2) received compensation of RMB 233 million from Xinjiang Meihua and MeiHua Holdings Group.
- Release of new production capacity. In 2025H1, the newly added production capacity of 400,000 tonnes of monosodium glutamate was fully operational. The increase in methionine sales reflects the market's acceptance of the company's additional 20,000-tonne methionine production capacity, which is scheduled for completion in 2024. Similarly, the increase in lysine sales indicates that the market has accepted the company's additional production capacity of 100,000 tonnes of methionine, which is scheduled for completion in 2024.
- ▶ Breakthroughs have been made in the internationalization process. The company's first overseas production base in Kazakhstan started construction in 25H1. The investment target for the first phase of Kazakhstan's development is approximately USD350 million. The company plans to manufacture and sell animal nutrition and high-end amino acid products in the first stage of development.

What's Different

- Product prices are under pressure. In 2023H1, demand for monosodium glutamate in the food and beverage market remained sluggish, resulting in weak downstream customer demand and prices for monosodium glutamate remaining low. According to Sublime China, the average 25H1 monosodium glutamate price was around RMB 7180 per tonne (-9.1% YoY). Since 2024, the price of xanthan gum has gradually fallen back to a relatively reasonable level, and new production in the 25H1 market has further put pressure on its price. According to Sublime China, the average xanthan gum price in 25H1 decreased by 13.7% year on year to approximately RMB 21,990 per tonne. Due to increased overseas demand, methionine and 98% lysine prices will gradually rise from 2024H2. However, due to a lack of integration between methionine and 98% lysine divisions, new production capacity continues to emerge in the market, putting pressure on prices. Prices of methionine and 98% lysine failed to continue their upward trend in 2024H1, falling back to the level seen in 2024H1.
- The cost of raw materials and energy has decreased. In 25H1, corn kernels accounted for around 54.9% of the total production cost (compared to 58.2% in 24H1). The average price of corn kernels in 25H1 was about RMB 1,780 per tonne (-14.3% YoY). In 25H1, the total cost of corn kernels decreased by 1.7%, primarily due to a year-on-year decrease in the average corn price. Coal costs represent the main energy cost. In 25H1, coal accounted for approximately 16.0% of the total production cost (In 24H1, 16.6%). In 25H1, the average unit cost of coal was approximately RMB 349 per tonne, representing a year-on-year decrease of 10.3%. The group's main production base has its own power plant which purchases coal directly from local mines with which it has signed long-term contracts. This ensures a steady supply of low-cost coal.

Action

➤ **Profit forecast.** We expect that the company's net profit in 2025-2027 will be 3.039 billion yuan, 3.350 billion yuan, and 3.647 billion yuan. Considering the valuation of comparable companies in the same industry, we have given the company PE of 8.5x for 2025, which corresponds to TP of RMB10.29. Calculated at a Hong Kong dollar to Chinese yuan exchange rate of 0.91, the corresponding target price is HKD11.30. We give the company a "Buy" rating.

Risks

Risk of product price fluctuations, risk of raw material price fluctuations.



分析师介绍

分析师庄怀超,本科毕业于北京航空航天大学,硕士毕业于香港大学金融学专业,主要覆盖化工和新材料行业。

该分析师 2022-2024 年曾任职于海通国际研究部,团队 2022 年获得过亚洲货币第一名,该分析师 2025 年加入环球富盛理财有限公司,继续覆盖化工和新材料行业。环球富盛理财有限公司是一家香港的持牌券商机构,成立于 2014 年。

该分析师曾在 wind 发布报告超过 500 篇,主要覆盖行业包括化肥、农药、气体、炸药、氟化工、分子筛、电解液和合成生物学等行业。覆盖的公司包括:东岳集团、环球新材国际、中国心连心化肥、中化化肥、阜丰集团、中国三江化工、中国联塑、浦林成山、米高集团、中国石油化学、中国旭阳集团、彩客新能源、天德化工、理文化工等。



微信: zhuangcharles

邮箱: charles.zhuang@gpf.com.hk

电话: (852) 9748 7114; (86) 188 01353 3537



COMPANY RATING DEFINITION

The Benchmark: Hong Kong Hang Seng Index

Time Horizon: 6 to 18 months

Time Henzem. 6 to	7 10 1110111110	
Rating		Definition
Buy	买入	Relative Performance>15%; or the fundamental outlook of the Company or sector is favorable.
Accumulate	收集	Relative Performance is 5% to 15%;
Name	-l- 1.1	or the fundamental outlook of the Company or sector is favorable.
Neutral	中性	Relative Performance is -5% to 5%; or the fundamental outlook of the Company or sector is neutral.
Reduce	减持	Relative Performance is -5% to -15%;
Sell	卖出	or the fundamental outlook of the Company or sector is unfavorable. Relative Performance < -15%;
OCII	大山	or the fundamental outlook of the Company or sector is unfavorable.

SECTOR RATING DEFINITION

The Benchmark: Hong Kong Hang Seng Index

Time Horizon: 6 to 18 months

Rating		Definition	
Outperform	跑赢大市	Relative Performance>5%;	
		or the fundamental outlook of the sector is favorable.	
Neutral	中性	Relative Performance is -5% to 5%;	
		or the fundamental outlook of the sector is neutral.	
Underperform	跑输大市	Relative Performance<-5%;	
•		Or the fundamental outlook of the sector is unfavorable.	

DISCLOSURE OF INTERESTS

- (1) The Analysts and their associates do not serve as an officer of the issuer mentioned in this Research Report.
- (2) The Analysts and their associates do not have any financial interests in relation to the issuer mentioned in this Research Report.
- (3) Global Prosperity Financial Company Limited and/or its subsidiaries do not hold equal to or more than 1% of the market capitalization of the issuer mentioned in this Research Report.
- (4) Global Prosperity Financial Company Limited and/or its subsidiaries have not had investment banking relationships with the issuer mentioned in this Research Report within the preceding 12 months.
- (5) Global Prosperity Financial Company Limited and/or its subsidiaries are not making a market in the securities in respect of the issuer mentioned in this Research Report.
- (6) Global Prosperity Financial Company Limitedand/or its subsidiaries have not employed an individual serving as an officer of the issuer mentioned in this Research Report. There is no officer of the issuer mentioned in this Research Report associated with Global Prosperity Financial Company Limited and/or its subsidiaries.

DISCLAIMER

This Research Report does not constitute an invitation or offer to acquire, purchase or subscribe for securities by Global Prosperity Financial Company Limited. Global Prosperity Financial Company Limited and its group companies may do business that relates to companies covered in research reports, including investment banking, investment services, etc. (for example, the placing agent, lead manager, sponsor, underwriter or invest proprietarily).

Any opinions expressed in this report may differ or be contrary to opinions or investment strategies expressed orally or in written form by sales persons, dealers and other professional executives of Global Prosperity Financial Company Limited group of companies. Any opinions expressed in this report may differ or be contrary to opinions or investment decisions made by the asset management and investment banking groups of Global Prosperity Financial Company Limited.

Though best effort has been made to ensure the accuracy of the information and data contained in this Research Report, Global Prosperity Financial Company Limited does not guarantee the accuracy and completeness of the information and data herein. This Research Report may contain some forward-looking estimates and forecasts derived from the assumptions of the future political and economic conditions with inherently unpredictable and mutable situation, so uncertainty may contain. Investors should understand and comprehend the investment objectives and its related risks, and where necessary consult their own financial advisers prior to any investment decision.

This Research Report is not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation or which would subject Global Prosperity Financial Company Limited and its group companies to any registration or licensing requirement within such jurisdiction.

© 2025 Global Prosperity Financial Company Limited. All Rights Reserved.

Unit 2301, 23/F., 308 Central Des Voeux, 308 Des Voeux Road Central, Sheung Wan, Hong Kong